HIV Specific T Cell Priming 48. Palmer BE, Boritz E, Wilson CC (2004) Effects of sustained HIV-1 plasma viremia on HIV-1 Gag-specific CD4+ T cell maturation and function. J Immunol 172: 3337–3347. 49. Okoye A, Meier-Schellersheim M, Brenchley JM, Hagen SI, Walker JM, et al. (2007) Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 204: 2171–2185. 50. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233–236. 51. Brown SA, Stambas J, Zhan X, Slobod KS, Coleclough C, et al. (2003) Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity. J Immunol 171: 4140–4148. 52. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906–1908. 53. Malhotra U, Holte S, Zhu T, Delpit E, Huntsberry C, et al. (2003) Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. J Virol 77: 2663–2674. 54. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, et al. (1999) HIV- 1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 5: 518–525. 55. Pantaleo G, Soudeyns H, Demarest JF, Vaccarezza M, Graziosi C, et al. (1997) Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci U S A 94: 9848–9853. 56. Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, et al. (2007) Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol 81: 4199–4214. 57. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365–1371. 58. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, et al. (2000) Immune control of HIV-1 after early treatment of acute infection. Nature 407: 523–526. 59. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, et al. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197: 563–571. 60. Sekaly RP (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7–12. 61. Ott DE, Nigida SM Jr, Henderson LE, Arthur LO (1995) The majority of cells are superinfected in a cloned cell line that produces high levels of human immunodeficiency virus type 1 strain MN. J Virol 69: 2443–2450. 62. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, et al. (1998) Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 72: 7992–8001. 63. Engelmayer J, Larsson M, Lee A, Lee M, Cox WI, et al. (2001) Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol 75: 2142–2153. PLoS ONE | www.plosone.org 13 January 2009 | Volume 4 | Issue 1 | e4256